公开(公告)号：KR1020080065722A

公开(公告)日：2008-07-15

申请号：KR1020070002715

申请日：2007-01-10

Applicant: 한국화학연구원

Inventor： 전동주 ,  노재성 ,  송종환 ,  이계형 ,  김익연 ,  박창민 ,  소원영 ,  이지선 ,  김은주 ,  강남숙 ,  천혜경 ,  조영식 ,  송진숙 ,  배명애 ,  김지현 ,  조중명 ,  노성구 ,  현영란 ,  이철순 ,  이재일 ,  유성은

IPC: C07D231/12 ,  C07D401/04 ,  C07D403/10 ,  C07D413/04

Abstract: A novel compound is provided to show excellent activity on PDE-4 enzymes and high selectivity on other PDE enzymes, thereby being used as a therapeutic agent of inflammation related diseases, arthritis, atopic dermatitis, leukemia, various cancers and degenerative brain diseases with little side effects. A 1-[1-(3,4-dialkoxyphenyl)-alkyl]-1H-pyrazole compound is represented by a formula(1) and is prepared by reacting a halo-benzyl compound represented by a formula(2) with a pyrazole compound represented by a formula(3). In the formula(1), each R1 and R2 is independently H, linear or branched saturated or unsaturated C1-7 alkyl which may be substituted or unsubstituted by halogen, C3-7 cycloalkyl, (C3-7)cycloalkyl(C1-7)alkyl, aryl or heteroaryl, ar(C1-5)alkyl, or ar(C1-5)alkoxy, or the R1 and R2 may be linked to each other by C1-3 alkylene; each R3, R4 and R5 is independently H, phenyl, pyridinyl, N-oxypyridinyl, linear or branched saturated and unsaturated C1-7 alkyl, C3-7 cycloalkyl, (C3-10)cycloalkyl(C1-7)alkyl, halogen, cyano, nitro, amino, mono- or di(C1-7)alkylamino, mono or di(C1-7)alkylaminocarbonyl, C3-7 cycloalkylamino, 3 to 7-membered saturated or unsaturated hetero-ring including O, N or S, guanidinyl, ureido, benzyl, benzyloxy, formyl, C1-7 alkanoyl, C1-7 alkoxy, (C1-7)alkoxy(C1-7)alkyl, hydroxy(C1-7)alkyl, carboxyl, or (C1-7)alkoxycarbonyl; R6 is linear or branched saturated and unsaturated C1-7 alkyl, C3-7 cycloalkyl, (C3-10)cycloalkyl(C1-7)alkyl, phenyl, phenoxy, benzyl, benzyloxy, C1-7 alkoxy, or (C1-7)alkoxy(C1-7)alkyl. A pharmaceutical composition for treating or preventing diseases related to airway inflammation, arthritis, atopic dermatitis, leukemia, cancer or degenerative brain diseases comprises the 1-[1-(3,4-dialkoxyphenyl)-alkyl]-1H-pyrazole derivative as an effective ingredient.

Abstract translation: 提供了一种新型化合物，以显示对PDE-4酶的优异活性和对其他PDE酶的高选择性，从而被用作炎症相关疾病，关节炎，特应性皮炎，白血病，各种癌症和退行性脑病的治疗剂 效果。 1-（1-（3,4-二烷氧基苯基） - 烷基] -1H-吡唑化合物由式（1）表示，通过式（2）表示的卤代苄基化合物与吡唑化合物 由公式（3）表示。 在式（1）中，每个R 1和R 2独立地为H，可被卤素取代或未取代的直链或支链饱和或不饱和C 1-7烷基，C 3-7环烷基，（C 3-7）环烷基（C 1-7） 烷基，芳基或杂芳基，芳（C 1-5）烷基或芳（C 1-5）烷氧基，或者R 1和R 2可以被C 1-3亚烷基相互连接; 每个R 3，R 4和R 5独立地为H，苯基，吡啶基，N-氧代吡啶基，直链或支链饱和和不饱和C 1-7烷基，C 3-7环烷基，（C 3-10）环烷基（C 1-7）烷基，卤素，氰基 ，硝基，氨基，单或二（C1-7）烷基氨基，单或二（C1-7）烷基氨基羰基，C3-7环烷基氨基，3至7元饱和或不饱和杂环，包括O，N或S，胍基 （C 1-7）烷基，羟基（C 1-7）烷基，羧基或（C 1-7）烷氧基羰基;（C 1-7）烷氧基， R6是直链或支链饱和和不饱和的C1-7烷基，C3-7环烷基，（C3-10）环烷基（C1-7）烷基，苯基，苯氧基，苄基，苄氧基，C1-7烷氧基或（C1-7） 烷氧基（C 1-7）烷基。 用于治疗或预防与气道炎症，关节炎，特应性皮炎，白血病，癌症或退行性脑疾病相关的疾病的药物组合物包括1- [1-（3,4-二烷氧基苯基） - 烷基] -1H-吡唑衍生物作为有效的 成分。

公开(公告)号：KR1020080012621A

公开(公告)日：2008-02-12

申请号：KR1020060073717

申请日：2006-08-04

Applicant: 한국화학연구원 ,  한올바이오파마주식회사

Inventor： 천혜경 ,  김광록 ,  이상달 ,  정원훈 ,  김희연 ,  이종철 ,  이정화 ,  이경 ,  김성욱 ,  전성수

IPC: C07D307/68 ,  A61K31/341 ,  A61P3/10 ,  A61P3/06

CPC classification number: C07D307/68

Abstract: Furan-2-carboxylic acid derivatives are provided to inhibit formation of sugars or lipids and promote absorption of sugars by activating AMPK(AMP(adenosine monophosphate)-activated protein kinase), so that the furan-2-carboxylic acid derivatives are useful for prevention and treatment of metabolic syndrome including diabetes, obesity, hyperlipidemia, hypercholesterolemia, fatty liver and steatohepatitis. Furan-2-carboxylic acid derivatives represented by the formula(1), wherein X is hydrogen or halogen, n is 1, 2 or 3, m is 0, 1 or 2 and R is hydrogen or C1-4 alkyl, are prepared by reacting compounds represented by the formula(2) with compounds represented by the formula(3) in organic solvent in the presence of base in which Y is triphenylphosphonium bromide salt, triphenylphosphonium iodide salt or benzothiazol-2-sulfonyl. A composition for prevention or treating metabolic syndrome comprises the furan-2-carboxylic acid derivatives represented by the formula(1).

Abstract translation: 提供呋喃-2-羧酸衍生物以抑制糖或脂质的形成，并通过活化AMPK（AMP（腺苷一磷酸）活化的蛋白激酶）促进糖的吸收，使得呋喃-2-羧酸衍生物可用于预防 和代谢综合症的治疗，包括糖尿病，肥胖症，高脂血症，高胆固醇血症，脂肪肝和脂肪性肝炎。 由式（1）表示的呋喃-2-羧酸衍生物，其中X是氢或卤素，n是1,2或3，m是0,1或2，R是氢或C 1-4烷基，是由 将式（2）表示的化合物与式（3）表示的化合物在有机溶剂中，在Y是三苯基溴化鏻盐，三苯基碘化鏻盐或苯并噻唑-2-磺酰基的碱存在下反应。 用于预防或治疗代谢综合征的组合物包括由式（1）表示的呋喃-2-羧酸衍生物。

公开(公告)号：KR100753017B1

公开(公告)日：2007-08-30

申请号：KR1020060046860

申请日：2006-05-25

Applicant: 한국화학연구원

Inventor： 노재성 ,  전동주 ,  송종환 ,  이계형 ,  박창민 ,  소원영 ,  강남숙 ,  홍석주 ,  천혜경 ,  조영식 ,  김기영 ,  배명애 ,  송진숙 ,  노성구 ,  현영란 ,  이운영 ,  김용은 ,  강봉균 ,  이혜련 ,  유성은

IPC: A61K31/437 ,  A61P35/00

Abstract: A pharmaceutical composition for treating or preventing arthritis, atopic dermatitis, tumor and degenerative brain diseases comprising 7-(3,4-Dialkoxyphenyl)-pyrazolo[1,5-a]pyrimidine compounds is provided to inhibit activity of PDE-4(phosphodiesterase-4) and reduce side effects such as vomiting by reducing HARBS(high-affinity rolipram binding sites) affinity. The pharmaceutical composition for treating or preventing arthritis, atopic dermatitis, tumor and degenerative brain diseases comprises 7-(3,4-Dialkoxyphenyl)-pyrazolo[1,5-a]pyrimidine compounds represented by the formula(1), wherein R1 and R2 are independently hydrogen atom, linear or branched saturated or unsaturated (C1-C7)alkyl, linear or branched saturated or unsaturated (C1-C7)alkyl containing halogen atom, (C3-C7)cycloalkyl, 3-membered to 7-membered heterocycloalkyl containing oxygen, nitrogen or sulfur in a hetero aromatic ring, (C4-C10)cycloalkyl(C1-C7)alkyl, 3-membered to 7-membered heterocycloalkyl(C1-C7)alkyl containing oxygen, nitrogen or sulfur in a hetero ring, phenyl, benzyl or allyl group; R3 is hydrogen atom, halogen atom, formyl, linear or branched and saturated or unsaturated (C1-C7)alkyl, (C1-C7)alkylketone, (C1-C7)alkoxy, (C1-C7)alkoxy (C1-C7)alkyl, hydroxy(C1-C7)alkyl group, carboxylic acid, carboxyl(C1-C7)alkylester, carboxyl(C1-C7)alkylamide, amino, or mono or di(C1-C7)alkylaminocarbonyl; and R4 is hydrogen atom, formyl, linear or branched saturated or unsaturated (C1-C7)alkyl, (C3-C7)cycloalkyl, (C1-C7)alkoxy, (C1-C7)alkoxy (C1-C7)alkyl, hydroxy(C1-C7)alkyl ketone, (C1-C10)alkylcarboxylic acid, carboxyl(C1-C10)alkylester, carboxyl(C1-C10)alkylamide, amino, mono or di(C1-C7)alkylamino, mono or di(C1-C7)alkylaminocarbonyl, (C3-C7)cycloalkylamine, morpholine, morpholine oxide, piperidine, piperazine, piperazine oxide or aryl group.

Abstract translation: 用于治疗或预防关节炎，特应性皮炎，肿瘤和退行性脑疾病，其包括7-（3,4-二烷氧基） - 吡唑并提供[1,5-a]嘧啶化合物抑制PDE-4的活性（phosphodiesterase-的药物组合物 4）并通过减少HARBS（高亲和力咯利普兰结合位点）亲和力来减少副作用，例如呕吐。 用于治疗或预防关节炎，特应性皮炎，肿瘤和退行性脑疾病的药物组合物包含7-（3,4-二烷氧基） - 吡唑并[1,5-a]嘧啶化合物由式（1）表示，其中R1和R2 （C 1 -C 7）烷基，含有卤素原子的直链或支链饱和或不饱和（C 1 -C 7）烷基，（C 3 -C 7）环烷基，含有3至7元杂环烷基的3元至7元杂环烷基 （C4-C10）环烷基（C1-C7）烷基，在杂环中含有氧，氮或硫的3元至7元杂环烷基（C1-C7）烷基，苯基 ，苄基或烯丙基; （C 1 -C 7）烷基，（C 1 -C 7）烷氧基，（C 1 -C 7）烷氧基（C 1 -C 7）烷基，（C 1 -C 7）烷氧基， （C 1 -C 7）烷基，羧酸，羧基（C 1 -C 7）烷基酯，羧基（C 1 -C 7）烷基酰胺，氨基或单或二（C 1 -C 7）烷基氨基羰基; （C 1 -C 7）烷基，（C 3 -C 7）环烷基，（C 1 -C 7）烷氧基，（C 1 -C 7）烷氧基（C 1 -C 7）烷基，羟基（C 1 -C 7）烷基， C1-C7）烷基酮，（C1-C10）烷基羧酸，羧基（C1-C10）烷基酯，羧基（C1-C10）烷基酰胺，氨基，单或二（C1-C7）烷基氨基，单或二（C1-C7 ）烷基氨基羰基，（C3-C7）环烷基胺，吗啉，氧化吗啉，哌啶，哌嗪，哌嗪氧化物或芳基。

公开(公告)号：KR1020070087953A

公开(公告)日：2007-08-29

申请号：KR1020060017372

申请日：2006-02-22

Applicant: 영진약품 주식회사 ,  한국화학연구원

Inventor： 김성수 ,  천혜경 ,  이상달 ,  안진희 ,  강남숙 ,  김기영 ,  강승규 ,  정원훈 ,  김성규 ,  김선영 ,  권재홍 ,  손상권

IPC: C07D231/04 ,  C07D237/04

CPC classification number: Y02P20/55 ,  C07D231/04 ,  C07D237/04 ,  C07D243/02 ,  C07D403/06 ,  C07D403/12 ,  C07D405/06 ,  C07D405/12 ,  C07D409/06 ,  C07D417/12

Abstract: A cyclic hydrazide derivative having a beta-amino group is provided to inhibit the activity of DPP-IV, thereby being useful for treating various diseases mediated by the DPP-IV. The cyclic hydrazide derivative having a beta-amino group is represented by the formula(1), wherein R1 is a group represented by the structural formula(a) or (b), R2 is H, C1-6 alkyl, C3-6 cycloalkyl, C1-6 haloalkyl, or a group represented by the structural formula(a), (b), (c), (d), (e), (f), (g), or (h)[wherein R^a is independently H, C1-6 alkyl, C3-6 cycloalkyl, C1-6 alkoxy, OCH2O, OCF3, phenoxy, halogen, CN, NO2, CF3, COOR^b or NR^bR^c(wherein each R^b and R^c is independently H, C1-6 alkyl or C3-6 cycloalkyl), R^d is a group represented by the structural formula(a), (b), (i), (j), (k), (l), or (m), R^e is C1-6 alkyl, C3-6 cycloalkyl, or a group represented by the structural formula(a) or (b), R^f is halogen, NR^b, R^c, a group represented by the structural formula(n) or (o), -S-heteroayl, tetrahydroisoquinoline, thiazolidine, proline, piperidine-4-carboxylic acid or tetrahydropyrimidine(where X is O or S)], and n is an integer from 1 to 3. The method comprises the steps of: (a) performing a condensation reaction of an amino acid represented by the formula(2) and a cyclic hydrazine represented by the formula(3) to obtain a compound represented by the formula(4); (b) reacting the compound of the formula(4) with chloroacetyl chloride to obtain a compound represented by the formula(6); (c) reacting the compound of the formula(6) with an R2 substituted nucleophilic compound to obtain a compound represented by the formula(5); and (d) deprotecting the compound of the formula(5). In the reaction formula(2), BOC is a protecting group, and each R1, R2, and n is the same as defined above.

Abstract translation: 提供具有β-氨基的环状酰肼衍生物以抑制DPP-IV的活性，从而可用于治疗由DPP-IV介导的各种疾病。 具有β-氨基的环状酰肼衍生物由式（1）表示，其中R 1是由结构式（a）或（b）表示的基团，R 2是H，C 1-6烷基，C 3-6环烷基 或者由结构式（a），（b），（c），（d），（e），（f），（g）或（h） a独立地是H，C 1-6烷基，C 3-6环烷基，C 1-6烷氧基，OCH 2 O，OCF 3，苯氧基，卤素，CN，NO 2，CF 3，COOR b或NR b R c c（其中每个R b和 （a），（b），（i），（j），（k），（j），（k） 1）或（m）R e是C 1-6烷基，C 3-6环烷基或由结构式（a）或（b）表示的基团，R f是卤素，NR b， c，由结构式（n）或（o）表示的基团，-S-杂芳基，四氢异喹啉，噻唑烷，脯氨酸，哌啶-4-甲酸或四氢嘧啶（其中X为O或S）]，n为 从1到3的整数。该方法包括以下步骤：（a）pe （2）表示的氨基酸与式（3）表示的环状肼的缩合反应，得到式（4）表示的化合物。 （b）使式（4）的化合物与氯乙酰氯反应，得到式（6）表示的化合物; （c）使式（6）化合物与R2取代的亲核化合物反应得到式（5）表示的化合物; 和（d）使式（5）的化合物脱保护。 在反应式（2）中，BOC为保护基，R1，R2和n各自与上述相同。

公开(公告)号：KR100704009B1

公开(公告)日：2007-04-04

申请号：KR1020050080383

申请日：2005-08-30

Applicant: 한국화학연구원

Inventor： 공영대 ,  천혜경 ,  전문국 ,  조영식 ,  황종연 ,  최형섭 ,  전현숙 ,  황순희 ,  송진숙 ,  김지현 ,  유성은

IPC: C07D311/70 ,  C07D409/12 ,  C07D401/12

CPC classification number: C07D311/58 ,  C07D405/12 ,  C07D409/12 ,  C07D409/14

Abstract: 본 발명은 신규 6-알킬아미노-2-메틸-2'-(
N- 메틸치환술폰아미도)메틸-2
H- 1-벤조피란 유도체와, 조합화학 합성기술 중 하나인 평형합성법을 이용하여 상기한 신규 화합물을 고효율로 합성하는 방법, 그리고 상기한 신규 화합물이 우수한 5-라이폭시게네이즈(5-LO) 저해효과를 나타내므로 관련 류코트리엔(LTA4, B4, C4, D4)의 활성으로 유발되는 염증질환, 류마티스성 관절염, 대장염(Colitis), 천식, 건선 등의 예방 및 치료제로 사용하는 용도에 관한 것이다.
조합화학 합성, 평형 합성, 5-라이폭시게네이즈, 항염증 질환 치료제, 약리학적 효능, 2'-술폰아미도메틸벤조피란, 유사약물 라이브러리

公开(公告)号：KR1020070024838A

公开(公告)日：2007-03-08

申请号：KR1020050080383

申请日：2005-08-30

Applicant: 한국화학연구원

Inventor： 공영대 ,  천혜경 ,  전문국 ,  조영식 ,  황종연 ,  최형섭 ,  전현숙 ,  황순희 ,  송진숙 ,  김지현 ,  유성은

IPC: C07D311/70 ,  C07D409/12 ,  C07D401/12

CPC classification number: C07D311/58 ,  C07D405/12 ,  C07D409/12 ,  C07D409/14

Abstract: A novel 6-alkylamino-2-methyl-2-(N-methyl substituted sulfonamido)methyl-2H-1-benzopyran derivative is provided to show excellent 5-lipoxygenase(5-LO) inhibition effect, thereby being used for preventing and treating inflammatory diseases induced by related leukotrien(LTA4, B4, C4, D4), rheumatoid arthritis, colitis, asthma, and psoriasis. The 6-alkylamino-2-methyl-2-(N-methyl substituted sulfonamido)methyl-2H-1-benzopyran derivative is represented by the formula(1), where R^1 is C1-10 alkyl; phenyl; phenyl substituted by a substituent selected from the group consisting of C1-6 alkyl, C1-6 acyloxy, C1-10 alkoxyalkyl, and C1-10 dialkoxyalkyl; benzyl; benzyl substituted by a substituent selected from the group consisting of halogen, nitro, cyano, hydroxy, C1-6 alkyl and C1-6 alkoxy; phenethyl; pyridyl methyl; thiophene methyl; or thiophene methyl substituted by C1-6 alkyl, each R^2 and R^3 is independently H; or C1-6 alkyl, and R^4 is C1-10 alkyl; phenyl; phenyl substituted by a substituent selected from the group consisting of C1-6 alkyl and C1-6 alkoxy; or thiophene. The anti-inflammatory agent comprises the 6-alkylamino-2-methyl-2-(N-methyl substituted sulfonamido)methyl-2H-1-benzopyran derivative represented by the formula(1).

Abstract translation: 提供新的6-烷基氨基-2-甲基-2-（N-甲基取代亚磺酰氨基）甲基-2H-1-苯并吡喃衍生物，以显示出优异的5-脂氧合酶（5-LO）抑制作用，从而用于预防和治疗 由相关白细胞介素（LTA4，B4，C4，D4），类风湿关节炎，结肠炎，哮喘和牛皮癣引起的炎性疾病。 6-烷基氨基-2-甲基-2-（N-甲基取代亚磺酰氨基）甲基-2H-1-苯并吡喃衍生物由式（1）表示，其中R 1是C 1-10烷基; 苯基; 被选自C 1-6烷基，C 1-6酰氧基，C 1-10烷氧基烷基和C 1-10二烷氧基烷基的取代基取代的苯基; 苄基; 被选自卤素，硝基，氰基，羟基，C 1-6烷基和C 1-6烷氧基的取代基取代的苄基; 苯; 吡啶基甲基; 噻吩甲基; 或被C 1-6烷基取代的噻吩甲基，每个R 2和R 3独立地为H; 或C 1-6烷基，R 4是C 1-10烷基; 苯基; 被选自C 1-6烷基和C 1-6烷氧基的取代基取代的苯基; 或噻吩。 抗炎剂包含式（1）表示的6-烷基氨基-2-甲基-2-（N-甲基取代亚磺酰氨基）甲基-2H-1-苯并吡喃衍生物。

公开(公告)号：KR100689961B1

公开(公告)日：2007-03-08

申请号：KR1020050018325

申请日：2005-03-04

Applicant: 한국화학연구원

Inventor： 노재성 ,  전동주 ,  송종환 ,  이계형 ,  정준원 ,  박창민 ,  정순민 ,  김지영 ,  강남숙 ,  홍석주 ,  천혜경 ,  남지연 ,  장범수 ,  곽현정 ,  송진숙 ,  허준영 ,  양승돈 ,  전영호 ,  노성구 ,  이태규 ,  현영란 ,  조중명 ,  허용석 ,  윤정민 ,  유성은

IPC: C07D277/42 ,  A61P11/06 ,  A61P25/28

Abstract: 본 발명은 하기의 화학식 1로 표시되는 신규한 4-(3,4-디알콕시페닐)-2-아미노티아졸 화합물 또는 그의 약제학적으로 허용 가능한 염, 이의 제조 방법 및 이를 유효성분으로 함유하는 것을 특징으로 하는 천식 및 만성폐쇄성 폐질환(Chronic Obstructive Pulmonary Disease)을 포함한 염증관련 질환의 치료 및 알쯔하이머를 포함한 중추신경계통 질환의 치료, 예방을 위한 약제학적 조성물에 관한 것이다.
[화학식 1]

4-(3,4-디알콕시페닐)-2-아미노티아졸, PDE-4, 천식, 만성폐쇄성 폐질환, 염증관련 질환, 중추신경계 질환, 알쯔하이머.

公开(公告)号：KR1020060102765A

公开(公告)日：2006-09-28

申请号：KR1020050024688

申请日：2005-03-24

Applicant: 씨제이제일제당 (주) ,  한국화학연구원

Inventor： 김형래 ,  노재성 ,  서민정 ,  송보간 ,  손범석 ,  김정기 ,  김광록 ,  천혜경 ,  손영선 ,  하경식 ,  김해선 ,  박완제 ,  이장윤 ,  윤채옥

IPC: C07D417/06

CPC classification number: C07D417/06

Abstract: 본 발명은 5-(1,3-디아릴-1H-피라졸-4-일메틸렌)-티아졸리딘-2,4-디온 유도체 또는 이의 약제학적으로 허용가능한 염과 이의 제조방법 및 이를 유효활성 성분으로 함유하는 항암제 조성물에 관한 것이다.
5-(1,3-디아릴-1H-피라졸-4-일메틸렌)-티아졸리딘-2,4-디온, 세포분열저해제, CDC25B, 탈인산화효소, 항암제

公开(公告)号：KR100622667B1

公开(公告)日：2006-09-19

申请号：KR1020040069245

申请日：2004-08-31

Applicant: 한국화학연구원

Inventor： 최중권 ,  하재두 ,  안진희 ,  강승규 ,  천혜경 ,  김광록 ,  이상달

IPC: C07C63/337

Abstract: 본 발명은 PTP1B(protein tyrosine phosphatase 1B), CD45, LAR(Leukocyte Antigen-Related), Cdc25A, Cdc25B, Cdc25C, Yop, PP1, VHR(vaccina human-related), Prl-3과 같은 단백질 포스파타제(protein phosphatase, PPase)에 대하여 우수한 약리학적 억제활성을 가지고 있어 자가면역 질병, 급성 및 만성 염증, 제1형 및 제2형 당뇨병, 손상된 글루코스 내성, 인슐린 저항성, 비만, 암 등 악성질병과 관련된 질병의 치료 및 예방에 유효한 다음 화학식 1로 표시되는 신규 나프틸옥시아세트산 유도체와 이의 약제학적으로 허용 가능한 염과, 이 화합물의 제조방법, 그리고 이 화합물을 유효성분으로 함유하는 약제조성물에 관한 것이다.

상기 화학식 1에서, R
1 , R
2 , R
3 , R
4 , R
5 , R
6 , R
7 및 R
8 은 각각 발명의 상세한 설명에서 정의한 바와 같다.
나프틸옥시아세트산, 단백질 포스파타제, 당뇨병

公开(公告)号：KR100602191B1

公开(公告)日：2006-07-19

申请号：KR1020040016206

申请日：2004-03-10

Applicant: 한국화학연구원

Inventor： 공영대 ,  천혜경 ,  조영식 ,  서진수 ,  황종연 ,  박지연 ,  유성은

IPC: C07D311/76

CPC classification number: C07D311/70 ,  C07D405/12 ,  C07D407/12 ,  C07D409/12

Abstract: 본 발명은 신규 2,2'-이중치환-3,4-디하이드로-7,8-이중치환-6-알킬아미노 벤조피란 유도체와, 조합화학 합성기술 중 하나인 평형합성법을 이용하여 상기한 신규 화합물을 고효율로 합성하는 방법, 그리고 상기한 신규 화합물이 우수한 5-라이폭시게네이즈(5-LO) 저해효과를 나타내므로 관련 류코트리엔(LTA4, B4, C4, D4)의 활성으로 유발되는 염증질환, 류마티스성 관절염, 대장염(Colitis), 천식, 건선 등의 예방 및 치료제로 사용하는 용도에 관한 것이다.
조합화학 합성, 평형 합성, 5-라이폭시게네이즈, 항염증 질환 치료제, 약리학적 효능, 벤조피란, 유사약물 라이브러리